Medical
Medtronic agreed to sell Cornerstone Robotics' Sentire surgical robot alongside Hugo in some markets outside the US, as part of a deal of about $700 million.
A dated step forward on the record · Company-reported
What the source says
“Medtronic will distribute Sentire alongside its Hugo™ robotic-assisted surgery (RAS) system.”
What it means
Hugo, from Medtronic, is at stage 5 of 5 on our ladder: regulator-cleared or mass market. Its stage is set by other milestones on its record; this one adds to the history. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: The maker hasn't said whether people help it remotely.
More on Hugo
- The FDA cleared a Medtronic vessel-sealing instrument for use with Hugo. Medtronic expects Hugo to pass 50,000 completed operations this financial year.
- Medtronic asked the FDA to clear Hugo for general surgery, including hernia repair, and for gynecologic surgery.
- The first US operation with Hugo, a prostate removal, was done at Cleveland Clinic in February 2026.
- The FDA cleared Hugo for soft-tissue urology operations, such as on the prostate, kidney and bladder.
- Medtronic executives said supply chain and manufacturing problems slowed Hugo's rollout after the pandemic.
- Hugo received the CE mark, which allows it to be sold in Europe.